文献速递胃肠动力与功能性疾病

Rome IV与Rome III肠易激综合征的自然史及疾病影响:纵向随访研究

Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-05-03

该12个月纵向随访研究纳入1097名自报符合Rome IV或Rome III标准的肠易激综合征成人,成功随访638人(58.2%)。Rome IV组较Rome III组更常就诊于初级保健医生(44.7% vs 28.5%)和消化科医生(26.3% vs 12.4%),更常启用新治疗(73.0% vs 60.2%),症状更重且对日常生活影响更大,心理状况更差。结论认为Rome IV定义下的肠易激综合征自然史较Rome III更严重。

要点

  • Rome IV肠易激综合征患者较Rome III患者更常就诊于初级保健医生和消化科医生。
  • Rome IV患者更常启用新治疗且治疗转换次数更多,症状更重且对日常生活影响更大。
  • Rome IV患者更易报告持续性腹痛且心理状况更差,提示疾病负担更重。

核心结论

  • Rome IV标准定义的肠易激综合征自然史较Rome III标准更严重,对未来治疗试验有重要影响。

研究设计与样本

  • 为期12个月的纵向随访研究,基线纳入1097名自报符合Rome IV或Rome III标准的肠易激综合征成人,随访成功638人(58.2%)。

主要发现

  • 随访12个月时,Rome IV组较Rome III组更常因肠易激综合征症状就诊于初级保健医生(44.7% vs 28.5%;P < .001)或消化科医生(26.3% vs 12.4%;P < .001)。
  • Rome IV组更常启用新治疗(73.0% vs 60.2%;P = .001),且治疗转换次数显著更多(P = .007)。
  • 随访评估时,Rome IV组症状更严重、对日常生活影响更大、更易报告持续性腹痛、心理状况差的比例更高(所有分析P < .001)。

临床怎么用

  • 临床中依据Rome IV标准诊断的肠易激综合征患者可能疾病负担更重,需更积极评估症状与心理状况。
  • 未来肠易激综合征治疗试验设计应考虑Rome IV标准下更严重的自然史,可能影响样本量与终点选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is a chronic functional bowel disorder diagnosed using the Rome criteria, which have evolved since their original description 30 years ago. Little is known about the effects on the natural history of IBS of moving to the latest iteration, Rome IV, from the previous Rome III criteria. We conducted a 12-month longitudinal follow-up study to examine this. METHODS: We collected complete demographic, symptom, mood, and psychological health data at baseline from 1097 adults who self-identified as having IBS and met either Rome IV or Rome III criteria. At 12 months, we collected data regarding IBS symptom severity and impact, consultation behavior, treatments commenced, and psychological health. We examined whether subsequent disease behavior in Rome IV- or Rome III-defined IBS differed. RESULTS: At 12 months, 638 (58.2%) of the 1097 participants were followed up successfully. Of these, 452 met Rome IV criteria and 186 met Rome III criteria at baseline. During the 12-month study period, individuals with Rome IV IBS were significantly more likely to have seen a primary care physician (44.7% vs 28.5%; P < .001) or a gastroenterologist (26.3% vs 12.4%; P < .001) for their IBS symptoms, were significantly more likely to have commenced a new treatment (73.0% vs 60.2%; P = .001), and cycled through significantly more treatments (P = .007), for their IBS compared with those with Rome III IBS. At follow-up evaluation, individuals with Rome IV IBS had more severe symptoms, which had a significantly greater impact on activities of daily living, were more likely to report continuous abdominal pain, and a higher proportion showed poor psychological health, compared with those with Rome III IBS (P < .001 for all analyses). CONCLUSIONS: The natural history of IBS defined according to Rome IV criteria is more severe than that of Rome III-defined IBS. This has important implications for future treatment trials in IBS.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Goodoory VC, Houghton LA, Yiannakou Y, et al. Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study. Clin Gastroenterol Hepatol. 2021. PMID: 33957271. doi:10.1016/j.cgh.2021.04.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。